Endo to Acquire Paladin Labs for $1.6B in Cash, Stock Deal

Endo Health Solutions

today announced that it has reached a definitive agreement to acquire Paladin Labs

, ("Paladin Labs") a leading Canada-based specialty pharmaceutical company, in a stock and cash transaction valued at approximately $1.6 billion of which approximately 98% will be paid in shares of stock as described below.  The acquisition accelerates Endo's strategic transformation to a leading global specialty healthcare company and creates a platform for future growth in North America and internationally.  Pursuant to the acquisition, each of Endo and Paladin Labs will be acquired by a newly-formed Irish holding company ("New Endo").  At $77.00 (CAD) per Paladin Labs share, the transaction represents a 20% premium to Paladin Labs' share price of $63.91 as of November 4, 2013, and is expected